HOMEPRODUCTSSERVICESCOMPANYCONTACTFAQResearchDictionaryPharmaMobileSign Up FREE or Login

[Continuous postmenopausal estrogen-progesterone therapy].

Abstract
In this study menopausal symptoms, endometrial histology, uterine bleeding pattern, plasma lipid concentrations, bone mineral loss, body weight and blood pressure have been evaluated in postmenopausal women who received continuous conjugated equine estrogens and medrogestone over a 1 year treatment period. By the third month of therapy we detected a significant (p < 0.01) improvement in postmenopausal symptomatology. At the 6th and 12th month, endometrial biopsy specimens revealed atrophic endometrium in all women. Uterine bleeding episodes were observed especially during the first months of treatment. Amenorrhoea was found in all patients only after 8 months of therapy. By the 6th month of therapy, we observed a significant (p < 0.01) decrease of plasma cholesterol and low-density lipoprotein cholesterol levels. Instead, plasma high-density lipoprotein and triglycerides concentrations didn't show significant variation from baseline values. No significant changes in bone mineral density could be detected after 12 months of treatment. Body weight and blood pressure were not significantly altered from baseline. This study suggests that continuous conjugated equine estrogens plus medrogestone treatment appears to be an interesting and safe manner to administer postmenopausal hormone replacement therapy. This regimen could represent a good alternative to sequential estroprogestin therapy in women who do not tolerate withdrawal bleeding.
AuthorsP Affinito, G A Tommaselli, R Morgera, M Rinaldi, P Di Mauro, C Nappi
JournalMinerva ginecologica (Minerva Ginecol) Vol. 45 Issue 3 Pg. 77-85 (Mar 1993) ISSN: 0026-4784 [Print] ITALY
Vernacular TitleEPRT continua in postmenopausa.
PMID8392669 (Publication Type: English Abstract, Journal Article)
Chemical References
  • Estrogens, Conjugated (USP)
  • Lipoproteins
  • Triglycerides
  • Medrogestone
Topics
  • Amenorrhea (chemically induced)
  • Atrophy
  • Biopsy
  • Dose-Response Relationship, Drug
  • Endometrial Hyperplasia (pathology)
  • Endometrium (drug effects, pathology)
  • Estrogen Replacement Therapy
  • Estrogens, Conjugated (USP) (administration & dosage, pharmacology)
  • Female
  • Humans
  • Lipoproteins (blood)
  • Medrogestone (administration & dosage, pharmacology)
  • Middle Aged
  • Osteoporosis, Postmenopausal
  • Triglycerides (blood)
  • Uterine Hemorrhage (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research network!


Choose Username:
Email:
Password:
Verify Password: